Results 11 to 20 of about 8,503,937 (347)
Circulation, 2022 Cardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to substantial reductions in cardiovascular events.
Joshua J. Joseph +8 more
semanticscholar +1 more source
RMD Open, 2023 Objectives This study aimed to assess the performance of cardiovascular risk (CVR) prediction models reported by European Alliance of Associations for Rheumatology and European Society of Cardiology recommendations to identify high-atherosclerotic CVR ...
Maria G Tektonidou +3 more
doaj +1 more source
Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events.
New England Journal of Medicine, 2022 BACKGROUND Childhood cardiovascular risk factors predict subclinical adult cardiovascular disease, but links to clinical events are unclear. METHODS In a prospective cohort study involving participants in the International Childhood Cardiovascular ...
D. Jacobs +18 more
semanticscholar +1 more source
Residual cardiovascular risk [PDF]
European Heart Journal Supplements, 2016 Residual cardiovascular risk is often associated with lipid abnormalities, such as atherogenic dyslipidaemia (AD). Dyslipidaemias are one of the determinants of the risk of developing atherosclerotic cardiovascular disease. In addition to low-density lipoprotein (LDL) particles, which are the most atherogenic lipoproteins, other apolipoprotein B ...
FERRARI, Roberto, Catapano, Alberico L.
openaire +3 more sources
RMD Open, 2023 Background To examine blood pressure (BP) and lipid treatment eligibility in antiphospholipid syndrome (APS) according to European Alliance of Associations for Rheumatology (EULAR) and European Society of Cardiology (ESC) recommendations.Methods ...
Maria G Tektonidou +3 more
doaj +1 more source
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
New England Journal of Medicine, 2022 BACKGROUND Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF ...
S. Ytterberg +12 more
semanticscholar +1 more source
Aging and Cardiovascular Risk [PDF]
BioMed Research International, 2015 As part of the aging process, our bodies accumulate increasing damage at the tissue, cellular and molecular levels, leading to a loss of function and to an increased risk of morbidities and of mortality. Increasing life expectancy has been associated with increasing risk of aging-associated diseases, including cardiovascular disease (CVD).
Javier González Gallego +3 more
openaire +3 more sources
Arterial Stiffness and Cardiovascular Risk in Hypertension.
Circulation Research, 2021 Arterial stiffness, a leading marker of risk in hypertension, can be measured at material or structural levels, with the latter combining effects of the geometry and composition of the wall, including intramural organization.
P. Boutouyrie +3 more
semanticscholar +1 more source
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
Medicina, 2021 A 78-year-old man came to our attention after undergoing coronary computed tomography angiography documenting multivessel coronary artery disease. He was started on treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor ...
Federica Fogacci +3 more
doaj +1 more source
Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment
Frontiers in Cardiovascular Medicine, 2022 Atherosclerosis is a predecessor of numerous cardiovascular diseases (CVD), which often lead to morbidity and mortality. Despite the knowledge of the pathogenesis of atherosclerosis, an essential gap in our understanding is the exact trigger mechanism. A
A. Poznyak +6 more
semanticscholar +1 more source